Relmada Therapeutics plans a phase three trial of NDV-1, an extended-release form of gencitabine and docetaxel for bladder cancer. The company expects to enroll its first patient within Q1 if the IND clears in January-February. The company reported $202 million of cash and marketable securities, which it said takes it out through 2029.
RLMD · Relmada Therapeutics, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Relmada Therapeutics appointed Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer, Urology & Uro-Oncology on November 16, 2026. He will lead clinical development across its pipeline, including the planned Phase 3 SPECTRUM registrational program for NDV-01.
RealMata reported that 12 of 14 evaluable NDV01 patients remained in complete response at 18 months, including 7 of 8 BCG-unresponsive patients, plans IND submissions by year-end 2026, and holds $202.1 million funding operations through 2029.
Relmada Therapeutics, Inc. reported $202.1 million in cash, cash equivalents and short-term investments, expected to fund operations through 2029. NDV-01 and sepranolone IND submissions remain on track for year-end 2026.
Relmada Therapeutics reported a nine-month net loss of $45,828,300, versus $37,517,400. It plans U.S. IND filings for NDV-01 and sepranolone by year-end 2026 and says existing liquidity funds operations for at least 12 months.
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q3 FY26 earnings call · Nov 12, 2026TL;DR. NDV-01 delivered durable Phase 2 responses and favorable tolerability while remaining on track for a year-end 2026 IND submission, and $202.1 million of liquidity is expected to fund operations through 2029. The main negatives were two Month 15 progressions to muscle-invasive disease and higher operating cash use and net losses.
- + NDV-01 showed durable 18-month responses, with 86% of evaluable 12-month complete responders remaining in complete response.
- + NDV-01's Phase 2 safety profile remained favorable, with no Grade ≥3 treatment-related adverse events, serious adverse events, or discontinuations.
- + The NDV-01 CMC program remained on track for a year-end 2026 IND submission, with a manufacturing plan intended to supply the Phase 3 program through completion.
- + The registrational Phase 3 program was renamed SPECTRUM.
- + Cash, cash equivalents, and short-term investments totaled $202.1 million and were expected to fund operations through 2029.
- + Updated 12-month Phase 2 results showed a 94% anytime complete-response rate, a 77% 12-month complete-response rate, and 100% progression-free and cystectomy-free survival through 12 months.
- − Two BCG-naïve patients with T1 disease progressed to muscle-invasive T2a disease at the Month 15 assessment.
- − Third-quarter R&D expense increased to $9.2 million from $4.0 million, driven partly by study preparation, manufacturing, storage, and compensation costs.
- − Third-quarter net cash used in operating activities rose to $12.6 million from $6.7 million.
- − Third-quarter net loss widened to $13.9 million, or $0.12 per basic and diluted share, from $10.1 million, or $0.30 per share.
- − Nine-month net cash used in operating activities increased to $37.3 million from $31.2 million.
- − Nine-month net loss increased to $45.8 million, or $0.44 per basic and diluted share, from $37.5 million, or $1.16 per share.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| 12-month landmark CR | 77% | Month 12 | — |
| Anytime CR | 94% | Interim P2 data | — |
| BCG-unresponsive subgroup 12-month CR rate | 73% | Updated 12-month efficacy results | — |
| BCG-unresponsive subgroup anytime CR rate | 96% | Updated 12-month efficacy results | — |
| BCG-unresponsive subgroup evaluable patients who reached 18 months remained in CR | 88% | Initial 18-month durability results | — |
| Cystectomy Free Survival | 100% | Month 12 | — |
| evaluable patients who reached 18 months remained in CR | 86% | Initial 18-month durability results | — |
| Grade ≥ 3 TR AEs & DCs | 0% | Interim P2 data | — |
| patients in complete response (CR) at 12 months continued into the long-term extension (LTE) | 23 | Initial 18-month durability results | — |
| Progression Free Survival | 100% | Month 12 | — |
| Cash, cash equivalents, and short-term investments balance | $217.7M | As of June 30, 2026 | — |
| Net cash used in operating activities | $9.6M | the three months ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RLMD
this stock
Relmada Therapeutics, Inc.
|
$304.61M | -40.9% | -73.2% | — | 10.2% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.01B | +18.3% | +46.2% | 34.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$97.81B | +22.5% | +20.8% | 20.9 | 2.1% |
|
MRNA
Moderna, Inc.
|
$79.63B | +567.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.15B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 16, 2026
- This year
- 20
Relmada Therapeutics appointed Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer, Urology & Uro-Oncology on November 16, 2026. He will lead clinical development across its pipeline, including the planned Phase 3 SPECTRUM registrational program for NDV-01.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RLMD | -35.6% | -11.1% | -60.4% | -20.3% | -40.9% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | -31.7% | -5.5% | -56.9% | -16.9% | -48.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.